Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 7/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9942847 | 0.91 | CA12 (0.40) | CA12CA9DDR1ARMPO | |
| SCHEMBL9942843 | 0.84 | DDR1 (0.40) | CA12CA9DDR1AR | |
| SCHEMBL9942848 | 0.83 | CA12 (0.35) | CA12CA9DDR1ARMPO | |
| SCHEMBL1660345 | 0.83 | CA12 (0.38) | CA12CA9DDR1ARMPO | |
| SCHEMBL9942861 | 0.82 | AR (0.37) | CA12CA9DDR1AR | |
| SCHEMBL4717715 | 0.82 | DDR1 (0.40) | CA12CA9DDR1AR | |
| SCHEMBL9942853 | 0.81 | AR (0.35) | CA12CA9DDR1AR | |
| SCHEMBL9942672 | 0.80 | CA12 (0.41) | CA12CA9DDR1ARMPO | |
| SCHEMBL9942855 | 0.79 | KDM4E (0.33) | CA12CA9AR | |
| SCHEMBL14773371 | 0.79 | AR (0.34) | CA12CA9DDR1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2476671-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| EP-2468732-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2463278-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |